Ardelyx, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ARDX, updated each market day.
ARDX AI Sentiment
AI sees no strong directional signal for Ardelyx, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Ardelyx, Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Sector
Exchange
Market Cap
$1,503,366,727
Cap Tier
Employees
489
Headquarters
FREMONT, CA
Listed Since
June 19, 2014
Website
ARDX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ARDX Volatility
Ardelyx, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
